计划状态
招聘阶段
第 1 阶段允许先接受免疫治疗
是CRC 指导的试验
没有标签
MSI-H/ MMRd、MSS/ MMRp评论
AB248: CD8+ T cell-selective IL-2 with over 500-fold preference for CD8+ T cells over other immune cell types.
Pembrolizumab: anti PD-1, immunotherapy.
AB248 alone or in combination with pembrolizumab. Prior anti PD-1/ L1 checkpoint inhibitor seems OK, but not prior immunotherapy that targets IL-2, IL-7, or IL-15 receptors. For solid tumors.
| 地点 | 位置状态 |
|---|---|
| 美国 | |
|
希望之城 加利福尼亚州杜阿尔特 91010 |
招聘 |
|
加利福尼亚大学洛杉矶分校 加利福尼亚州洛杉矶 90095 |
招聘 |
|
UCSF San Francisco, California 94143 |
招聘 |
|
Yale 康涅狄格州纽黑文 06510 |
招聘 |
|
迈阿密大学 佛罗里达州迈阿密 33136 |
招聘 |
|
奥卡拉肿瘤中心 佛罗里达州奥卡拉 34474 |
招聘 |
|
麻省总医院 马萨诸塞州波士顿 02114 |
招聘 |
|
达纳法伯癌症研究所 马萨诸塞州波士顿 02215 |
招聘 |
|
卡马诺斯癌症研究所 密歇根州底特律 48201 |
招聘 |
|
华盛顿大学 密苏里州圣路易斯 63110 |
招聘 |
|
Rutgers 新泽西州新不伦瑞克 08901 |
招聘 |
|
NYU 纽约州纽约市 10016 |
招聘 |
|
纪念斯隆-凯特琳癌症中心 纽约州纽约市 10065 |
招聘 |
|
UNC 莱恩伯格综合癌症中心 北卡罗来纳州教堂山 27599 |
招聘 |
|
萨拉-坎农研究所 田纳西州纳什维尔 37203 |
招聘 |
|
Virginia Commonwealth 弗吉尼亚州里士满 23298 |
招聘 |
联系方式
纳入标准
纳入标准
* Age ≥18 years of age at the time consent is signed.
* Has adequate end organ function per laboratory testing.
* Pregnancy prevention requirements
* Has measurable disease per RECIST 1.1 as assessed by the local site Investigator/radiology.
* Has a performance status of 0 or 1 on Eastern Cooperative Oncology Group scale.
* Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts
排除标准
排除标准：
* Has a diagnosis of immunodeficiency.
* Has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years.
* Has known active CNS metastases and/or carcinomatous meningitis.
* Has an active autoimmune disease that has required systemic treatment in the past 2 years.
* Has an active infection requiring systemic therapy.
* Inability to comply with study and follow-up procedures.
* Has had a severe hypersensitivity reaction (Grade ≥3) to treatment with pembrolizumab, another monoclonal antibody, or has history of any hypersensitivity to any components of the study treatments or any of their excipients.
* Has received prior systemic anticancer therapy including investigational agents within 4 weeks (or, if shorter, within 5 half-lives for kinase inhibitors) prior to first dose of study treatment.
* Has received prior radiotherapy within 2 weeks of start of study treatment or has had a history of radiation pneumonitis.
* Receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.
* Has received previous treatment with another agent targeting the IL-2, IL-7, or IL-15 receptors.
* Is expected to require any other form of antineoplastic therapy while on study
